DrugPatentWatch Database Preview
Paratek Pharms Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for PARATEK PHARMS INC, and what generic alternatives to PARATEK PHARMS INC drugs are available?
PARATEK PHARMS INC has two approved drugs.
There are eleven US patents protecting PARATEK PHARMS INC drugs.
There are one hundred and ninety-eight patent family members on PARATEK PHARMS INC drugs in forty countries.
Summary for Paratek Pharms Inc
| International Patents: | 198 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Paratek Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | 7,553,828 | Start Trial | Y | Start Trial | |||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | 10,383,884 | Start Trial | Start Trial | ||||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | 9,724,358 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Paratek Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2010140682 | Start Trial |
| Canada | 3042514 | Start Trial |
| China | 104844472 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
